Zenicor (ZENI) investor relations material

Executive summary

• Revenue for Q1 2026 increased by 10% year-over-year to 7,770 KSEK, marking the best first quarter to date.

• Operating profit reached 559 KSEK, up from 158 KSEK in Q1 2025, with net profit at 165 KSEK versus a loss of -450 KSEK last year.

• Growth was driven by both new and existing customers, with a notable increase in order backlog by 1.9 MSEK during the quarter.

• Focus markets remain Sweden, Finland, and the UK, with sales through public tenders and direct to private healthcare providers.

Financial highlights

• Revenue: 7,770 KSEK in Q1 2026 (7,085 KSEK in Q1 2025), a 10% increase year-over-year.

• Operating profit: 559 KSEK (158 KSEK in Q1 2025).

• Net profit: 165 KSEK (-450 KSEK in Q1 2025).

• EPS: 0.01 SEK (-0.05 SEK in Q1 2025).

• Cash flow from operations: -2,337 KSEK; cash and cash equivalents at period end: 884 KSEK.

Outlook and guidance

• Continued focus on growth in Sweden, Finland, and the UK, with expectations for these markets to drive growth through 2027.

• Order backlog increased, indicating strong future revenue streams.

• Screening studies (SAFER, STROKESTOP 3) expected to present results in 2028, potentially supporting further market expansion.